Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. by Phuan, Puay-Wah et al.
UCSF
UC San Francisco Previously Published Works
Title
Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset 
of minimal function CFTR mutants.
Permalink
https://escholarship.org/uc/item/20t0z843
Journal
Scientific reports, 9(1)
ISSN
2045-2322
Authors
Phuan, Puay-Wah
Tan, Joseph-Anthony
Rivera, Amber A
et al.
Publication Date
2019-11-27
DOI
10.1038/s41598-019-54158-2
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRtS |         (2019) 9:17640  | https://doi.org/10.1038/s41598-019-54158-2
www.nature.com/scientificreports
nanomolar-potency ‘co-
potentiator’ therapy for cystic 
fibrosis caused by a defined subset 
of minimal function CFTR mutants
Puay-Wah Phuan1*, Joseph-Anthony tan1, Amber A. Rivera1, Lorna Zlock2,  
Dennis W. nielson3, Walter E. Finkbeiner2, Peter M. Haggie1 & Alan S. Verkman1,4
Available CFTR modulators provide no therapeutic benefit for cystic fibrosis (CF) caused by many loss-
of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channel, including N1303K. We previously introduced the concept of ‘co-potentiators’ (combination-
potentiators) to rescue CFTR function in some minimal function CFTR mutants. Herein, a screen of 
~120,000 drug-like synthetic small molecules identified active co-potentiators of pyrazoloquinoline, 
piperidine-pyridoindole, tetrahydroquinoline and phenylazepine classes, with EC50 down to ~300 nM 
following initial structure-activity studies. Increased CFTR chloride conductance by up to 8-fold was 
observed when a co-potentiator (termed ‘Class II potentiator’) was used with a classical potentiator 
(‘Class I potentiator’) such as VX-770 or GLPG1837. To investigate the range of CFTR mutations 
benefitted by co-potentiators, 14 CF-associated CFTR mutations were studied in transfected cell 
models. Co-potentiator efficacy was found for CFTR missense, deletion and nonsense mutations in 
nucleotide binding domain-2 (NBD2), including W1282X, N1303K, c.3700A > G and Q1313X (with 
corrector for some mutations). In contrast, CFTR mutations G85E, R334W, R347P, V520F, R560T, 
A561E, M1101K and R1162X showed no co-potentiator activity, even with corrector. Co-potentiator 
efficacy was confirmed in primary human bronchial epithelial cell cultures generated from a N1303K 
homozygous CF subject. The Class II potentiators identified here may have clinical benefit for CF caused 
by mutations in the NBD2 domain of CFTR.
Cystic fibrosis (CF) is caused by loss of function mutations in the cystic fibrosis transmembrane conductance reg-
ulator (CFTR) protein, a cAMP-activated chloride channel1. More than 2000 CF-causing CFTR variants have been 
identified (http://genet.sickkids.on.ca/Home.html). CFTR modulators have been developed that rescue defective 
cellular processing and cell-surface targeting of mutant CFTRs (correctors) and defective channel gating (potenti-
ators) to restore CFTR anion transport1–3. The potentiator Kalydeco (ivacaftor/VX-770) has been approved for CF 
subjects with gating mutations, including G551D-CFTR and now 38 additional mutations2. The corrector/poten-
tiator combinations Orkambi (VX-770 plus lumacaftor/VX-809) and Symdeko (VX-770 plus tezacaftor/VX-661) 
have been approved for CF subjects that are homozygous for the most common CF-causing CFTR mutation, 
F508del, or who have one F508del allele and a residual function CFTR mutation2. Trikafta, a triple drug combina-
tion consisting of two correctors and one potentiator, has recently been approved for CF subjects with one or two 
F508del alleles2,4–6. Trikafta and future CFTR modulators may benefit up to 90% of CF subjects2.
Therapeutic approaches are needed for CFTR mutations that are unlikely to benefit from existing modu-
lators – the so-called ‘remaining 10%’2,7,8. Non-responsive minimal function CFTR mutations are distributed 
throughout the CFTR protein and are associated with low CFTR function due to defective channel processing, 
cell-surface trafficking, and/or channel gating9. One such CFTR mutation is N1303K, a missense point mutation 
located in nucleotide binding domain 2 (NBD2), which is the 5th most common CFTR mutation worldwide 
accounting for ~2.5% of CFTR mutations (www.cftr2.org). Other minimal function missense CFTR mutants 
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are found in membrane spanning domain (MSD) 1, including G85E and R334W, and MSD2, including L1077P 
and M1101K. These four CFTR mutants are found in ~1.4% of ~88,000 CF subjects in the CFTR2 database. 
Premature termination codon (PTC) mutations also have no available therapy, including G542X located in NBD1 
and W1282X located in NBD2, which are the 2nd and 4th most common CFTR mutations (5% and 4% allele fre-
quency in CFTR2 database, respectively).
We previously reported that VX-770, when used in combination with a second potentiator identified 
by high-throughput screening, increased chloride channel function of N1303K-CFTR and the truncated 
W1282X-CFTR protein product by ~8-fold compared with VX-770 alone1,10. This combination-potentiator 
(co-potentiator) approach was effective as well in increasing the chloride channel function of G551D-CFTR, with 
~50% improvement compared with VX-770 alone11. Building on these initial results, here we explored the poten-
tial utility of co-potentiators for additional minimal function CFTR mutants and identified, by high-throughput 
screening, novel co-potentiator scaffolds with nanomolar potency. In addition, we provide evidence to support a 
new classification system (Class I vs. Class II) for potentiators, which predicts synergy in CFTR activation.
Results
CFTR mutational space specificity of co-potentiator ASP-11. The arylsulfonamide-pyrrolopyridine 
ASP-11 (Fig. 1A) was found previously to increase chloride current by ~8-fold over that produced by a high 
concentration of VX-770 in transfected FRT cells expressing N1303K-CFTR or CFTR1281 (the truncation product 
generated by W1282X-CFTR)10,11. To investigate the CFTR mutational space specificity for ASP-11, 12 additional 
minimal function CFTR mutants were studied (Fig. 1B and Suppl. Table 1). The nine missense mutants stud-
ied are located throughout the CFTR protein and included mutations in MSD1 (G85E, R334W, R347P), NBD1 
(S492F, V520F, R560T, A561E) and MSD2 (L1077P, M1101K). G85E, V520F and R560T are class II mutations, 
similar to F508del-CFTR9. Two C-terminal PTC mutations, R1162X, and Q1313X, were studied based on the 
prior W1282X-CFTR data showing benefit of co-potentiators10. Lastly, the complex CFTR mutant c.3700A > G 
was also tested, which introduces a point mutation (I1234V-CFTR) that retains CFTR activity, or a cryptic splice 
site resulting in a 6-amino acid deletion in NBD2, p.Ile1234_Arg1239del (I1234del-CFTR)12. Testing of these 
NBD2 truncation and deletion mutations was motivated by biochemical and electrophysiological evidence sug-
gesting that incomplete NBD2, including CFTR polypeptides as short as 1217 amino acids, may sometimes allow 
partial CFTR cell-surface expression and function13,14.
As shown in Fig. 1C and summarized in Fig. 2, ASP-11 acted in synergy with VX-770 to increase chloride 
current in FRT cells expressing the NBD2 mutations I1234del- and Q1313X-CFTR by ~3–9-fold compared to 
VX-770. I1234del- and Q1313X-CFTR-expressing cells were also treated with VX-809 for 24 hours (to consider 
the effect of available CFTR therapeutics) with 2–3-fold greater currents observed. In contrast, the NBD1 muta-
tion S492F-CFTR showed limited forskolin-stimulated current and no response to VX-770 or ASP-11, though 
VX-809 increased the forskolin response. Qualitatively similar absence of ASP-11 effect was found for other 
CFTR mutations located in MSD1 (R334W), NBD1 (V520F and R560T), and MSD2 (L1077P and M1101K), 
although many of the mutants (R334W, L1077P, M1101K) showed some forskolin activation and VX-770 effect 
(Fig. 2). In contrast to Q1313X-CFTR (Fig. 2), the C-terminus PTC mutant R1162X-CFTR (predicted to truncate 
CFTR just after MSD2) did not respond to forskolin, VX-770, ASP-11 or VX-809.
Compounds that promote read-through of PTCs to generate full-length CFTR have shown limited efficacy 
in cell culture studies15–17. Though the read-through drug ataluren (PTC124) was ineffective in clinical trials18, 
newer compounds are in development. We investigated the ability of ASP-11 to activate chloride current in pre-
dicted W1282X-CFTR read-through products. G418 action on W1282X was found to insert mainly leucine or 
cysteine at position 128219, and ataluren to insert arginine17. FRT cell lines were generated that stably expressing 
W1282L-, W1282C- and W1282R-CFTR. W1282L-CFTR showed robust forskolin stimulation with little addi-
tional VX-770 or ASP-11 effect (Figs. 1D and 2). W1282C-CFTR showed less forskolin response but significant 
further effects of VX-770 and ASP-11, and W1282R-CFTR showed minimal function (Figs. 1D and 2). Together, 
the data as summarized in Fig. 2 suggest that several missense, deletion and truncation mutations in NBD2 may 
be amenable to co-potentiator action.
Classification of potentiators to predict synergy. Based on prior studies10,11,20, we hypothesized 
that distinct binding sites may be required to bind a potentiator and co-potentiator to rescue channel activity 
of CFTR mutants. We defined the potentiator VX-770 as a Class I compound, and co-potentiator ASP-11 as 
a Class II compound (Fig. 3A,D). Short-circuit current measurements in N1303K-CFTR-expressing FRT cells 
confirmed synergy when ASP-11 was added after VX-770 (Fig. 3Bi). Similar results were found for ASP-11 
added after GLPG1837 (Fig. 3Bii), suggesting that GLPG1837 is a Class I potentiator. Additions of P2, P3 and 
P5 (potentiator activity confirmed in separate studies, not shown) did not further increase current when added 
after VX-770 (Fig. 3Biii), indicating that these compounds also belong to Class I. Interestingly, VX-770 addi-
tion after GLPG1837 mildly reduced current (data not shown), consistent with competitive binding between 
VX-770 and GLPG1837 as reported for G551D-CFTR20. Another co-potentiator previously reported to activate 
W1282X-CFTR, W1282Xpot-C0110, activated N1303K-CFTR when used with VX-770 (Fig. 3Biv), demonstrating 
this compound is a Class II potentiator. Finally, two Class II potentiators, W1282Xpot-C01 and ASP-11, produced 
little activation when added together (Fig. 3Bv). In each experiment, CFTRinh-172 confirmed that current was 
from CFTR.
Studies on FRT cells expressing Q1313X-CFTR produced similar data (Fig. 3C). Addition of the Class I poten-
tiators VX-770 (Fig. 3Ci) or GLPG1837 (Fig. 3cii) followed by the Class II potentiator apigenin showed synergy. 
In contrast, sequential additions of Class I potentiators P2, P3 and P5 did not elevate current following VX-770, 
whereas Class II potentiator ASP-11 did (Fig. 3ciii). As seen for N1303K-CFTR and G551D-CFTR20, VX-770 
added after GLPG1837 reduced current in Q1313X-CFTR expressing cells (Fig. 3civ). As summarized in Fig. 3D 
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for N1303K-CFTR, synergy was seen for Class I and Class II compounds used together, but not for combinations of 
Class I-Class I or Class II-Class II compounds. Similar results were seen for Q1313X-CFTR (Suppl. Figs. 1 and 2).
Novel co-potentiator scaffolds identified by high-throughput screening. Given the utility of 
co-potentiators as possible CF therapeutics for several minimal function CFTR mutants, a screen was done 
to identify novel co-potentiator scaffolds. Screening used FRT cells stably expressing W1282X-CFTR and the 
halide-sensitive EYFP-H148Q/I152L/F46L (YFP) that were treated for 24 hours with 3 μM VX-809 to increase 
CFTR1281 cell surface expression (Fig. 4A). Just prior to assay cells were treated for 10 min with test compounds at 
25 μM together with 20 μM forskolin and 15 nM VX-770. CFTR channel activity was deduced from the initial rate 
of YFP fluorescence quenching in response to addition of iodide-substituted phosphate buffered saline. Primary 
screening of 120,000 drug-like synthetic small molecules identified 212 compounds giving channel activity >50% 
of that produced by forskolin, VX-770 and 20 μM ASP-11 (Fig. 4B). After initial confirmation with plate reader 
assays, short-circuit current measurement revealed the 21 most active compounds of four chemical classes, 
which were further studied. The most active compounds included piperidinepyridoindole CP-A01, phenylaze-
pine CP-B01, tetrahydroquinoline CP-C01 and pyrazoloquinoline CP-D01 (Fig. 4C). Concentration-dependence 
Figure 1. Co-potentiator ASP-11 activity in minimal function CFTR mutants in transfected FRT cells. (A) 
Structure of ASP-11. (B) Location of minimal function CFTR mutants studied herein. (C) Representative short-
circuit current data in FRT cells expressing I1234del-CFTR, Q1313X-CFTR and S492F-CFTR in response to 
20 µM forskolin (fsk), 5 µM VX-770, 20 µM ASP-11 and 10 μM CFTRinh-172. As indicated, cells were treated 
with 3 µM VX-809 for 18–24 h prior to measurements. (n = 3) (D). Representative short-circuit current data in 
FRT cells expressing predicted W1282X-CFTR read-through products W1282L-CFTR, W1282R-CFTR and 
W1282C-CFTR (without and with VX-809 pretreatment) (n = 3). MSD, membrane spanning domain; NBD, 
nucleotide binding domain; R, regulatory domain.
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measurements in VX-809-corrected W1282X-CFTR-expressing FRT cells in the presence of forskolin and 5 μM 
VX-770 demonstrated an ~6-fold increase in VX-770 current with EC50 of 10 μM, 5 μM, 8 μM and 15 μM for 
CP- A01, B-01, C01 and D01, respectively (Fig. 4D). Each of these compounds added to VX-809-corrected FRT 
cells expressing W1282X-CFTR produced little current without VX-770 (Fig. 4E). As found for ASP-119,10, syn-
ergy of W1282X-CFTR activation by VX-770 and the new Class II potentiators did not depend on the order of 
compound addition (data not shown).
Structure-activity relationship studies of piperidinepyridoindole and pyrazoloquinoline 
co-potentiators. To establish structure-activity relationships, 240 commercially available piperidinepyri-
doindole analogs and 160 pyrazoloquinoline analogs were tested in FRT cells expressing W1282X-CFTR. 
Figure 5A summarizes the structural determinants for activity for the piperidinepyridoindoles reported in 
Table 1 (CP-Axx designations). In general, the methoxy substituent on the 4-position (R3) on the pyridoindole 
ring increased potency (compare A01 vs A534). N-methylation on the pyridoindole ring abolished activity (com-
pare A534 vs A600). For substituent R1 on the piperidine ring, substituted benzyl gave greatest activity (A061 
and A662). Other R1 substituents, including sulfonamide (A145), alkyl (A764) and carbocyclic (A714), reduced 
activity. Changing the benzylic carbon from methylene (CH2) to ketone (C=O) abolished activity (A815, A350 
and A956). A061 with R1 being 2,4-difluoro-benzyl was the most potent analog.
Figure 5B summarizes the structural determinants for the pyrazoloquinolines reported in Table 2 (CP-Dxx 
designations). The position of the methoxy on the quinoline ring affected activity as changing from the 4th to 
5th position greatly reduced potency (D038 vs D138). Replacing the electron-donating methoxy group to 
electron-neutral methyl group also reduced activity (D010 vs D136). For R3, pyridine (D003), benzyl (D035) 
and substituted methyl-pyrazole (D086) abolished activity. Substituted benzenes had a range of potencies with 
2,4-disubstituted compounds including 2-chloro-4-fluorobenzene (D018) and 2-chloro-4-nitrobenzene (D038) 
being the most potent. The D123 pyrazoloquinoline with R3 substituted with thiophene-quinoline heterocycle 
gave the best potency.
Short-circuit current measurements were done for the most potent piperidinepyridoindole (CP-A061) 
and pyrazoloquinoline (CP-D123). Figures 5C,D show data in N1303K- and Q1313X-expressing FRT cells. 
Following forskolin and VX-770, concentration-dependent increases in current were seen following addition of 
co-potentiators, with current fully inhibited by CFTRinh-172. The calculated EC50 values were 2.9 μM and 300 nM 
for CP-A061 and CP-D123, respectively, in the FRT cells expressing N1303K-CFTR. Similar EC50 values of 5 μM 
and 320 nM for CP-A061 and CP-D123 were found in FRT cells expressing Q1313X-CFTR.
Co-potentiator activity in human CF airway epithelial cell models and primary cell cultures. To 
test the efficacy of new co-potentiators in human airway cell models, short-circuit current was measured in 
16HBE14o- human airway epithelial cells in which the endogenous CFTR gene was edited to contain the N1303K 
Figure 2. Summary of short-circuit current responses to modulators for CFTR mutants in transfected 
FRT cells. Responses to indicated CFTR mutants with 20 μM forskolin, 5 µM VX-770, 20 µM ASP-11 
(with or without 3 µM VX-809 overnight). For reference, data shown for cells expressing wild type CFTR. 
Mean ± S.E.M., n = 3.
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mutation (16HBE-N1303Kge21) and in primary cultures of human bronchial epithelial cells from a N1303K 
homozygous CF subject. Addition of forskolin and then VX-770 to 16HBE-N1303Kge cells gave a limited 
response (Fig. 6A). Subsequent addition of CP-A061 or CP-D123 produced CFTRinh-172-inhibitable responses of 
~10 μA/cm2, ~6-fold greater that that produced by VX-770 alone. Increased short-circuit current was also found 
for these co-potentiators in the primary human bronchial epithelial cell cultures (Fig. 6B).
Discussion
This purpose of this study was to develop a therapeutic strategy for CF subjects with CFTR mutations that 
do not respond significantly to the available drugs Kalydeco, Orkambi and Symdeko. This work extended our 
prior data on CFTR modulators, called co-potentiators, that act in synergy with VX-770 to increase channel 
activity of W1282X-CFTR and N1303K-CFTR by ~8-fold, and of G551D-CFTR by ~1.5-fold, compared to 
VX-770 alone10,11. Here, high-throughput screening and preliminary structure-activity studies identified novel 
co-potentiator scaffolds with drug-like properties with EC50 down to 300 nM, which acted in synergy with 
VX-770 and other Class I potentiators to increase CFTR chloride current. An interesting observation was that 
the potentiator/co-potentiator paradigm was effective on a variety of missense, nonsense and deletion mutations 
specifically in NBD2 of CFTR. Whether analogous combination potentiators can be developed for residual or 
minimal function mutants in other regions of the CFTR protein, perhaps with next-generation corrector(s), is not 
known but warrants further consideration.
VX-770 is currently approved for CF subjects with one copy of one of 38 mutations located throughout the 
CFTR sequence, including MSD1 (e.g. D110H, E193K), MSD2 (A1067T, R1070W), NBD1 (G551D, D579G), 
NBD2 (G1244E, G1349D), and other regions (E56K, P67L in the lasso domain)2,22,23. Based on in silico docking 
and mutagenesis studies, two potential binding sites were identified for the Class I compounds VX-770 and 
GLPG183724. The putative binding sites are located at the interface of the CFTR transmembrane domains involv-
ing residues D924, N1138 and S1141, or residues F229, F236, Y304, F312 and F93124. Recently, cryo-electron 
microscopy confirmed that VX-770 and GLPG1837 bind at the same site within the protein-lipid interface in a 
pocket formed by transmembrane helices 4, 5 and 825. Evaluation of potential binding sites by alanine substitu-
tion revealed that a network of residues (including F236, Y304, F312 and F931, as well as L233, F305 and S308) 
interact directly with both VX-770 and GLPG183725. Using a pharmacological approach, we found evidence that 
several previously reported potentiators including P2, P3 and P5 also bind at or near the VX-770 and GLPG1837 
Figure 3. Definition of Class I and II CFTR potentiators. (A) Chemical structures of Class I and II potentiators. 
(B) Short-circuit current in FRT cells expressing N1303K-CFTR in response to forskolin and indicated 
potentiators. Concentrations: 20 μM forskolin, 5 μM VX-770, 20 μM ASP-11, 20 μM GLPG1837, 20 μM P2, 
20 μM P3, 20 μM P5, 20 μM W1282Xpot-C01, and 10 μM CFTRinh-172. C. Short-circuit current in FRT cells 
expressing Q1313X-CFTR in response to forskolin and indicated potentiators. Concentrations: as in panel B, 
and 25 μM apigenin. (D) Summary of relative N1303K-CFTR activation in response to combinations of Class I 
and Class II potentiators. Mean ± S.E.M., n = 3.
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binding site. Given the broad efficacy of VX-770 for mutations throughout the CFTR protein, and the absence 
of large differences in CFTR structure with vs. without bound potentiator, it is likely that Class I potentiators 
thermodynamically alter the closed-open equilibrium of CFTR25. The Class II potentiators identified here act in 
synergy with VX-770 and other Class I compounds to rescue the defective gating of CFTR mutations in NBD2. 
At present, the putative binding site(s) of Class II potentiators is unknown, though early in silico docking stud-
ies26 showed that genistein, which is structurally similar to the Class II potentiator apigenin, binds at the NBD 
dimer interface. We therefore speculate that the Class II potentiators may bind to CFTR in a manner that sta-
bilizes partial or misfolded NBD2 structurally or thermodynamically. Because potentiators may produce both 
long-range and local conformational changes, as well as thermodynamic alterations to increase conductance of 
mutant CFTRs, potentiator synergy screening as done here may be useful for selected mutations in other regions 
of the CFTR protein.
The results here suggest that a variety of missense, nonsense and deletion mutations in NBD2, including 
N1303K- and I1234del-CFTR, can be benefitted by two distinct potentiators. In prior studies on the responses of 
>50 rare CFTR missense mutations to VX-770 and VX-809, N1303K-CFTR was not responsive to VX-770 and 
showed very limited response to VX-80927. This is consistent with the notion that the N1303K mutation causes 
defective CFTR folding, regulation and gating9. Biochemical analysis of N1303K-CFTR processing in various cell 
systems, including FRT cells28 and 16HBE14o- cells21, showed little complex glycosylated CFTR (band C) with 
or without VX-809 (Hillary Valley and Martin Mense, personal communication). Previous studies on the rela-
tionship of CFTR glycosylation to function suggest that the addition of carbohydrate to CFTR is not a necessary 
prerequisite for CFTR targeting to the plasma membrane or functioning as a cAMP-stimulated chloride chan-
nel29,30. Our data showing significant current from three N1303K-CFTR expressing cell models suggest that some 
core glycosylated N1303K-CFTR is present on the plasma membrane. Han et al27. reported diverse responses to 
CFTR modulators – some mutations (P5L, G27R, S492F, Y1032C) responded to VX-809 but not VX-770, some 
(M348V) to VX-770 but not VX-809, and some (G85E, R560T, A561E, Y563N) with no response. We found 
robust activation of N1303K-CFTR with co-potentiators in the absence of a corrector in a human airway epithe-
lial cell line expressing endogenous levels of gene-edited CFTR (Fig. 6A). In primary human bronchial cell cul-
tures from a homozygous N1303K-CFTR subject, CP-A061 produced ~2.5 μA/cm2 of CFTRinh-172-inhibitable 
current (Fig. 6B). Based on measurements done using similarly cultured non-CF and CF human airway epithelial 
Figure 4. Novel co-potentiators identified by high-throughput screening. (A) Assay design. (B) Summary 
of screening workflow and results. (C) Chemical structures of novel co-potentiators identified by screening. 
(D) Representative short-circuit current data in FRT cells expressing W1282X-CFTR. Concentrations: 20 μM 
forskolin (fsk), 5 μM VX-770 (n = 3). (E) Effects of sequential addition of 20 μM forskolin followed by 20 μM 
of A-01, B-01, C-01 and D-01, and 5 μM of VX-770 in FRT cells expressing W1282X-CFTR. CFTRinh-172 was 
used at 10 μM in all experiments.
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cell cultures, we estimate that 2.5 μA/cm2 of CFTR current is equivalent to ~20% of wildtype CFTR activity, which 
is potentially of clinical benefit. This value would further increase with use of an effective corrector to increase 
N1303K-CFTR cell-surface expression.
It is hard to estimate the number CF subjects that might benefit from co-potentiator therapy. The N1303K 
allele is found in 2,147 subjects in the CFTR2 databases, of which 99 are homozygous and >400 would not be 
benefitted by VX-770 or therapies that targeting one F508del-CFTR allele. Similarly, c.3700A > G is found in 28 
subjects, of which 5 are homozygous. It is noted that many countries in which N1303K and c.3700A > G are prev-
alent do not contribute to the CFTR2 database31,32. We previously showed that ASP-11 activates G551D-CFTR, 
as do the new co-potentiators identified here (not shown). The G551D allele is found in ~3000 CF subjects 
in CFTR2, including 69 homozygous subjects. Although approved to treat 38 CF variants with residual func-
tions, Ivacaftor (VX-770) however does not fully restore CFTR function of some of these CF variants with gat-
ing mutations (e.g. G551D-CFTR)33 to wild-type level. Co-potentiator therapy might thus be used to further 
increase CFTR function, with greater health benefits for CF patients with these gating mutations. In addition, the 
co-potentiators were effective in increasing CFTR chloride current for several truncated forms of CFTR resulting 
from premature termination codons (PTCs) located in NBD2. PTCs result in nonsense-mediated degradation 
(NMD) of transcript resulting in reduced synthesis of truncated protein products34,35. CFTR transcript levels 
have been reported from ~10–75% of levels in non-CF cells36,37, though one study reported complete absence of 
W1282X-CFTR transcript in cells from a single CF subject38. Co-potentiators may thus be therapeutically benefi-
cial for PTCs in NBD2, alone if sufficient transcript is present, or in combination with other drugs such as NMD 
inhibitors or read-through agents.
Limited information has been reported on biological activities for the pyrazoloquinoline and 
piperidine-pyridoindole classes of compounds. Some acylated pyrazoloquinolines showed in vitro antibacterial 
activity by inhibition of bacterial serine/threonine protein kinases39. Pyrazoloquiolines from a chemical library 
screen were also identified as enhancers of siRNA delivery40. Piperidine-pyridoindoles have been reported as lig-
ands of 5-HT1A receptors41, and their amino-alkylated analogs showed anxiolytic activity in mice42. Synthetically, 
both pyrazoloquinoline and piperidine-pyridoindole scaffolds can be prepared in four-to-seven steps in a con-
vergent manner from commercially available starting chemicals to allow facile and rapid diversification of these 
scaffolds. CP-A061 and CP-D123 have drug-like properties, including the presence of multiple hydrogen bond 
Figure 5. Structure-activity analysis of piperidine-pyridoindole and pyrazoloquinoline co-potentiators. (A) 
Structural determinants of piperidine-pyridoindole (CP-Axxx) and (B) pyrazoloquinoline (CP-Dxxx) co-
potentiator activity. (C) Short-circuit current in FRT cells expressing N1303K-CFTR showing responses to 
20 µM forskolin (fsk), 5 µM VX-770, and indicated concentrations of CP-A061 (left) and CP-D123 (center). 
(right) Summary of concentration-dependence data. (D) Short-circuit current in FRT cells expressing Q1313X-
CFTR done as in panel C. (right) Summary of concentration-dependence data.
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acceptors, as well as aLogP, molecular weight, and topological polar surface areas of 4.39, 397 and 40.3 Å2, respec-
tively, for CP-A061, and 4.97, 451 and 95.9 Å2, respectively, for CP-D123.
In summary, the present study identified novel co-potentiator scaffolds with nanomolar potency that, in syn-
ergy with Class I potentiators such as VX-770, activated CFTRs with NBD2 mutations including N1303K-CFTR. 
Potentiator/co-potentiator combination therapy may be effective in a subset of minimal function missense, non-
sense and deletion mutations in CFTR that cause cystic fibrosis and are not responsive to current CFTR modu-
lator combinations.
Materials and Methods
Chemicals. VX-809, VX-770, GLPG1837 and CFTRinh-172 were purchased from Selleck Chemicals (Boston, 
MA). Potentiators P2 (PG-0143), P3 (SF-0343) and P5 (∆F508act-0244) were obtained from an in-house repository 
of CFTR modulators. For screening, 120,000 diverse drug-like synthetic compounds (ChemDiv Inc., San Diego, 
CA) were tested. Other chemicals were purchased from Sigma unless otherwise stated.
Complementary DNA constructs. Complementary DNAs (cDNAs) for the I1234del-, W1282C/L/R and 
Q1313X- mutants CFTRs were generated using standard techniques. In brief, gBLOCK gene fragment (Integrated 
DNA Technology, Coralville, IA) were synthesized and introduced into full-length CFTR cDNA in the vector 
pcDNA3.1/Zeo (+) (Invitrogen). For subcloning, I1234del-CFTR was generated using a HindIII site at position 
3171–3176 of the CFTR cDNA; for W1282C/L/R and Q1313X-CFTR a BstXI site at position 3801–3812 of CFTR 
cDNA was used. The mutated CFTR cDNAs were subcloned into vector pIRESpuro3 (Clontech, Mountain View, 
CA) using NheI and NotI restriction sites. All constructs were confirmed by sequencing.
Cell culture models. Fischer rat thyroid (FRT) cells were cultured in Kaign’s modified Ham’s F-12 medium 
supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 18 μg/ml 
myoinositol, and 45 μg/ml ascorbic acid. To generate FRT cells stably expressing I1234del-, W1282C/L/R and 
Q1313X-CFTR, cells were transfected with pIRESpuro3-based vectors and clonal cell lines were isolated after 
inclusion of 0.15 µg/ml puromycin (Invitrogen) in cell culture medium. FRT cell lines expressing wild type, 
Compound R1 R2 R3 EC50 (μM) Relative Vmax (%)*
A01 3-methoxy-benzyl H OMe 10 100
A061 2,4-difluoro-benzyl H OMe 2.0 100
A662 3,4-difluoro-benzyl H OMe 2.6 100
A666 H OMe 5.1 91
A357 benzyl H H 16 31
A534 3-methoxy-benzyl H H 13 24
A600 3-methoxy-benzyl Me H >30 4
A714 cyclohexyl H OMe >30 18
A815 H H >30 -4
A350 H OMe >30 7
A956 H OMe >30 6
A145 SO2-Me H OMe >30 7
A764 Me H OMe >30 6
Table 1. Structure-activity data of selected piperidine-pyridoindole analogs. *100% Vmax corresponds to 20 μM 
ASP-11.
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Compound R1 R2 R3 EC50 (μM) Relative Vmax (%)*
D001 OMe H 2-chlorobenzene 15 90
D003 OMe H 4-pyridine >30 1
D010 OMe H 4-fluorobenzene 3.6 24
D012 OMe H 3,4,5-trimethoxybenzene >30 3
D018 OMe H 2-chloro-4-fluoro-benzene 2.4 92
D025 OMe H 3-methyl-4-nitro-benzene >30 3
D035 OMe H >30 1
D036 OMe H 3-nitro-4-chloro-benzene >30 11
D038 OMe H 2-chloro-4-nitro-benzene 1.7 100
D086 OMe H >30 3
D123 OMe H 0.3 100
D136 Me H 4-fluorobenzene 18 11
D138 H OMe 2-chloro-4-nitro-benzene 3.4 21
Table 2. Structure-activity data of selected pyrazoloquinoline analogs. *100% Vmax corresponds to 20 μM ASP-11.
Figure 6. N1303K-CFTR activity in human airway epithelial cell cultures. (A) Short-circuit current in gene-
edited 16HBE14o- cells expressing N1303K-CFTR. Concentrations: 20 µM amiloride, 20 µM forskolin, 5 µM 
VX-770, 20 µM CP-A061 and CP-D123, and 10 µM CFTRinh-172. Representative original curves (left and 
center) and summary of changes in current (∆Isc) (right). Mean ± S.E.M., n = 3, *P < 0.05). (B) Short-circuit 
current in primary cultures of human bronchial epithelial cells from a homozygous N1303K-CFTR CF subject. 
Concentrations were as in panel A. Representative original curves (left and center) and summary of changes in 
current (∆Isc) (right). Mean ± S.E.M., n = 3, *P < 0.05.
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W1282X- and N1303K-CFTR were cultured as reported10,11,45. FRT cells lines expressing G85E-, R334W-, 
R347P-, S492F-, V520F-, R560T-, A561E-, L1077P-, M1101K- and R1162X-CFTR were a generous gift from 
Drs. Andras Rab and Jeong Hong (Emory University) and cultured as described27. Gene edited 16HBE14o- cells 
expressing N1303K-CFTR were provided by the CFFT Lab, and were cultured as described21.
Primary human bronchial and nasal epithelial cell cultures. Human bronchial epithelial cells isolated 
from a lung transplant from a N1303K homozygous CF subject were provided by Scott H. Randell (Marsico Lung 
Institute, The University of North Carolina at Chapel Hill, USA). The cells were obtained under protocol #03-1396 
approved by the University of North Carolina at Chapel Hill Biomedical Institutional Review Board. Cells were 
isolated, conditionally reprogrammed, and expanded as described10,46.
High-throughput screening. High-throughput screening was performed using a semi-automated screen-
ing platform (Beckman, Fullerton, CA) as described10. In short, FRT cells expressing W1282X and halide-sensitive 
YFP were plated onto 96-well tissue-culture plates at a density of 20,000 cells/well (black-walled, clear-bottom)
(Corning). The cells were grown for 24 h at 37 °C to ~90% confluency before treatment with 3 μM VX-809 for 
additional 24 hours. Cells were then washed twice with PBS. Cells were then added with 100 μl of PBS containing 
forskolin (10 μM), VX-770 (15 nM) and test compounds (25 μM) and incubated for 10 min prior to assay of CFTR 
activity. All plates contained wells with positive (5 μM VX-770 + 20 μM ASP-11) and negative (5 μM VX-770) 
controls. Assays were done using a BMG Labtech FLUOstar OMEGA plate reader (Cary, NC). Each well was 
read over 12 s with initial fluorescence intensity recorded for 2 s before addition of 100 μl of NaI-substituted PBS 
(137 mM NaCl replaced with NaI). Initial iodide influx rate was computed from fluorescence intensity using 
single exponential regression.
Short-circuit current measurements. Short-circuit current was measured on cells cultured on Snapwell 
clear permeable supports (Corning) as described10,11. Hemichambers were connected to a DVC-1000 voltage 
clamp (World Precision Instruments Inc., Sarasota, FL) via Ag/AgCl electrodes and 3 M KCl agar bridges for 
recording of the short-circuit current. For human airway epithelial cells, symmetrical HCO3−-buffered solutions 
(in mM: 120 NaCl, 5 KCl, 1 MgCl2, 1 CaCl2, 5 Hepes, 25 NaHCO3, 10 glucose, pH 7.4) for basolateral and apical 
side were used. For FRT cells, the basolateral membrane was permeabilized with 250 μg/ml amphotericin B, and 
experiments were done with a chloride gradient using a HCO3−-buffered solutions (Basolateral (mM): 120 NaCl, 
5 KCl, 1 MgCl2, 1 CaCl2, 5 Hepes, 25 NaHCO3, 10 glucose, pH 7.4; apical (mM): 60 NaCl, 60 mM sodium gluco-
nate, 5 KCl, 1 MgCl2, 1 CaCl2, 5 Hepes, 25 NaHCO3, 10 glucose, pH 7.4). All cells were equilibrated with 95% O2, 
5% CO2 and maintained at 37 °C during experiments.
Data analysis. For statistical analysis, GraphPad Prism software (GraphPad Inc., San Diego, CA, USA) was 
used. Statistical significance was determined using the Mann-Whitney test, with P < 0.05 considered significant. 
For determination of EC50 values, non-linear regression to a single-site inhibition model was used.
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